Literature DB >> 22484427

Activation of p53 following ionizing radiation, but not other stressors, is dependent on the proline-rich domain (PRD).

H G Campbell1, R Mehta, A A Neumann, C Rubio, M Baird, T L Slatter, A W Braithwaite.   

Abstract

The tumor suppressor protein, p53 is one of the most important cellular defences against malignant transformation. In response to cellular stressors p53 can induce apoptosis, cell cycle arrest or senescence as well as aid in DNA repair. Which p53 function is required for tumor suppression is unclear. The proline-rich domain (PRD) of p53 (residues 58-101) has been reported to be essential for the induction of apoptosis. To determine the importance of the PRD in tumor suppression in vivo we previously generated a mouse containing a 33-amino-acid deletion (residues 55-88) in p53 (mΔpro). We showed that mΔpro mice are protected from T-cell tumors but not late-onset B-cell tumors. Here, we characterize the functionality of the PRD and show that it is important for mediating the p53 response to DNA damage induced by γ-radiation, but not the p53-mediated responses to Ha-Ras expression or oxidative stress. We conclude that the PRD is important for receiving incoming activating signals. Failure of PRD mutants to respond to the activating signaling produced by DNA damage leads to impaired downstream signaling, accumulation of mutations, which potentially leads to late-onset tumors.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22484427     DOI: 10.1038/onc.2012.102

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  9 in total

1.  The Trp53 delta proline (Trp53ΔP) mouse exhibits increased genome instability and susceptibility to radiation-induced, but not spontaneous, tumor development.

Authors:  Cassandra J Adams; Jennifer S Yu; Jian-Hua Mao; Kuang-Yu Jen; Sylvain V Costes; Mark Wade; Jocelyn Shoemake; Olulanu H Aina; Reyno Del Rosario; Phuong Thuy Menchavez; Robert D Cardiff; Geoffrey M Wahl; Allan Balmain
Journal:  Mol Carcinog       Date:  2015-08-27       Impact factor: 4.784

2.  The proline rich domain of p53 is dispensable for MGMT-dependent DNA repair and cell survival following alkylation damage.

Authors:  Katherine Baran; Mao Yang; Christopher P Dillon; Leona L Samson; Douglas R Green
Journal:  Cell Death Differ       Date:  2017-07-28       Impact factor: 15.828

Review 3.  Illuminating p53 function in cancer with genetically engineered mouse models.

Authors:  Patty B Garcia; Laura D Attardi
Journal:  Semin Cell Dev Biol       Date:  2014-01-03       Impact factor: 7.727

Review 4.  Targeting the ubiquitin-mediated proteasome degradation of p53 for cancer therapy.

Authors:  Tiffany Devine; Mu-Shui Dai
Journal:  Curr Pharm Des       Date:  2013       Impact factor: 3.116

5.  Alpha-enolase is upregulated on the cell surface and responds to plasminogen activation in mice expressing a ∆133p53α mimic.

Authors:  Sonal Sawhney; Kylie Hood; Alisha Shaw; Antony W Braithwaite; Richard Stubbs; Noelyn A Hung; Janice A Royds; Tania L Slatter
Journal:  PLoS One       Date:  2015-02-02       Impact factor: 3.240

6.  Δ122p53, a mouse model of Δ133p53α, enhances the tumor-suppressor activities of an attenuated p53 mutant.

Authors:  T L Slatter; N Hung; S Bowie; H Campbell; C Rubio; D Speidel; M Wilson; M Baird; J A Royds; A W Braithwaite
Journal:  Cell Death Dis       Date:  2015-06-11       Impact factor: 8.469

7.  Chromatin remodeling protein MORC2 promotes breast cancer invasion and metastasis through a PRD domain-mediated interaction with CTNND1.

Authors:  Xiao-Hong Liao; Ye Zhang; Wen-Jie Dong; Zhi-Min Shao; Da-Qiang Li
Journal:  Oncotarget       Date:  2017-06-16

Review 8.  Molecular dynamic simulation insights into the normal state and restoration of p53 function.

Authors:  Ting Fu; Hanyi Min; Yong Xu; Jianzhong Chen; Guohui Li
Journal:  Int J Mol Sci       Date:  2012-08-03       Impact factor: 6.208

Review 9.  Deregulation and Targeting of TP53 Pathway in Multiple Myeloma.

Authors:  Katarina K Jovanović; Guillaume Escure; Jordane Demonchy; Alexandre Willaume; Zoe Van de Wyngaert; Meryem Farhat; Paul Chauvet; Thierry Facon; Bruno Quesnel; Salomon Manier
Journal:  Front Oncol       Date:  2019-01-09       Impact factor: 6.244

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.